C. Salado, Roura M, D. Kortazar, R. Mella, J. Gamiz & P. Villacé
INNOPROT, Parque tecnológico de Bizkaia, Edf. 502-1º, Bilbao, Spain
Alzheimer disease (AD) is characterized by brain depositions of the beta amyloid (βA). The βA is the amyloid precursor protein (APP) digestion product, which is released from the cell after β-secretase and γ-secretase proteolysis. Innoprot has developed a novel fluorescence cell-based assay for High Content Screening of new secretase inhibitors. In this work we used this model to screen a library of 1200 compounds. LP226A1 compound from Lipopharma S.L. was used as a positive control. LP226A1 is a new candidate to Alzheimer disease drug that has been validated both in cellular and animal models. After the screening campaign, twenty three compounds were chosen for further testing, based on the strength of the initial response and lack of cytotoxicity. Our results indicated that the pharmacological inhibition of secretases implicated in AD remains a valid strategy for drug screening.
|Click [+] for other articles on||The Market Place for Lab Automation & Screening||The Market Place|